Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. William Blair restated an “outperform” rating and issued a $5.00 price target on shares of Synthetic Biologics in a research report on Monday, May 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $3.92.

Shares of Synthetic Biologics (SYN) opened at 0.75 on Friday. The firm has a 50-day moving average of $0.58 and a 200 day moving average of $0.61. The firm’s market capitalization is $96.19 million. Synthetic Biologics has a 12-month low of $0.41 and a 12-month high of $1.90.

Synthetic Biologics (NYSEMKT:SYN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.03. On average, equities research analysts expect that Synthetic Biologics will post ($0.17) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Synthetic Biologics Inc (SYN) Stock Rating Lowered by ValuEngine” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://theolympiareport.com/2017/09/03/synthetic-biologics-inc-syn-stock-rating-lowered-by-valuengine.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Norges Bank bought a new position in Synthetic Biologics during the fourth quarter worth about $356,000. UBS Group AG increased its position in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after buying an additional 20,038 shares during the last quarter. Bank of New York Mellon Corp increased its position in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock worth $166,000 after buying an additional 7,962 shares during the last quarter. Susquehanna International Group LLP increased its position in Synthetic Biologics by 76.4% in the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock worth $107,000 after buying an additional 82,030 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Synthetic Biologics by 8,102.7% in the second quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock worth $639,000 after buying an additional 1,115,343 shares during the last quarter.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.